New hope for advanced stomach cancer: drug combo targets tumors after standard therapy fails
Disease control
Not yet recruiting
This study tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy can help people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working. About 30 adults aged 18-75 will receive the drug com…
Phase: NA • Sponsor: Qingxia Li • Aim: Disease control
Last updated May 11, 2026 20:49 UTC